Financials data is unavailable for this security.
View more
Year on year Sprint Bioscience AB grew revenues 60,725.30% from 83.00k to 50.49m while net income improved from a loss of 60.17m to a smaller loss of 438.00k.
Gross margin | 76.51% |
---|---|
Net profit margin | 17.31% |
Operating margin | 16.38% |
Return on assets | 41.28% |
---|---|
Return on equity | 128.58% |
Return on investment | 128.58% |
More ▼
Cash flow in SEKView more
In 2023, Sprint Bioscience AB increased its cash reserves by 69.31%, or 20.44m. The company earned 22.87m from its operations for a Cash Flow Margin of 45.30%. In addition the company generated 24.00k cash from financing while 2.45m was spent on investing.
Cash flow per share | 0.2217 |
---|---|
Price/Cash flow per share | 5.28 |
Book value per share | 0.2677 |
---|---|
Tangible book value per share | 0.2677 |
More ▼
Balance sheet in SEKView more
Current ratio | 1.47 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼